Cancer Immunology, Immunotherapy

Overview

Cancer Immunology, Immunotherapy is providing a timely and open access publication of original discovery and developments in basic and translational research in the field of cancer immunology and immunotherapy.

Editor-in-Chief

Haidong Dong

Societies and partnerships

Journal metrics

Journal Impact Factor: 5.1 (2024)

5-year Journal Impact Factor: 5.4 (2024)

Submission to first decision (median): 3 days

Downloads: 1.5M (2024)

Call for papers

Collection

Natural Killer cell therapy

View the webinar recording based on this Natural Killer Cell Therapy collection.

View all calls for papers

Latest articles

Simultaneous TGF-β and GITR pathway modulation promotes anti-tumor immunity in glioma
Daniela Lorizio
Manuela Silginer
Patrick Roth
Research Open access 28 June 2025 Article: 254
Dissecting response to neoadjuvant immunotherapy-treated melanoma using cancer-immunity cycle-associated signatures
S. C. M. A. Wijnen
P. Dimitriadis
C. U. Blank
Brief Report Open access 25 June 2025 Article: 253
T cell-derived small extracellular vesicles in cancer–immune interactions
Ma Janelle Chichoco Garcia
Su Su Thae Hnit
Yuling Wang
Review Open access 25 June 2025 Article: 252
Tumor-promoting function of paternally expressed gene 10 and its immunogenicity in inducing anti-tumor helper T cells in head and neck squamous cell carcinoma
Hiroki Komatsuda
Toshihiro Nagato
Hiroya Kobayashi
Research Open access 25 June 2025 Article: 251
Intratumoral IL12 mRNA administration activates innate and adaptive pathways in checkpoint inhibitor-resistant tumors resulting in complete responses
Jayalakshmi Lakshmipathi
Sreevidya Santha
Viswanathan Muthusamy
Research Open access 25 June 2025 Article: 250

View all articles

Journal updates

Cancer Immunology, Immunotherapy is now fully open access!

We are excited to announce that Cancer Immunology, Immunotherapy has now become a fully open-access (OA) journal as of 5^th January 2024. This means that we will only be publishing articles as Open Access meaning content will be freely available to readers worldwide, enabling the widest possible dissemination and reuse.
Springer Nature Oncology Webinar Series

Sign up for free online attendance.
Learn more about Springer Nature’s oncology titles

Discover the range of academic oncology titles at Springer Nature here.
Announcing new Editor-in-Chief: Dr. Haidong Dong

The journal is pleased to announce Dr. Haidong Dong has been named the new Editor-in-Chief of Cancer Immunology, Immunotherapy, effective January 1, 2020.

View all updates

Journal information

Electronic ISSN: 1432-0851
Print ISSN: 0340-7004
Abstracted and indexed in: AGRICOLA

BFI List

BIOSIS

Baidu

Biological Abstracts

CLOCKSS

CNKI

CNPIEC

Chemical Abstracts Service (CAS)

Cortellis Drug Discovery Intelligence

Current Contents/Life Sciences

DOAJ

Dimensions

EBSCO

EMBASE

Google Scholar

Japanese Science and Technology Agency (JST)

Medline

Naver

Norwegian Register for Scientific Journals and Series

OCLC WorldCat Discovery Service

Pathway Studio

Portico

ProQuest

PubMedCentral

Reaxys

SCImago

SCOPUS

Science Citation Index Expanded (SCIE)

Semantic Scholar

TD Net Discovery Service

Wanfang